Trial Profile
An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids Chronically
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Kyowa Kirin Pharmaceutical Development
- 08 Feb 2024 Status changed from recruiting to discontinued.
- 04 Mar 2021 Planned End Date changed from 1 Dec 2023 to 1 Dec 2022.
- 04 Mar 2021 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2022.